U.S. Biopharmaceuticals Market Set for $755 Billion Boom by 2032: Amgen, AbbVie, Pfizer & GSK Lead the Way

Leading players, including Amgen, AbbVie, Pfizer, and GSK, shape the sector's future with new drug approvals, blockbuster acquisitions, and expanding pipelines.

[June 12, 2025 | New York, NY] - The U.S. biopharmaceuticals market is experiencing strong momentum, driven by scientific innovation, major acquisitions, and late-stage drug pipeline activity. Recent forecasts project the market to grow at a compound annual growth rate (CAGR) of 7.4%, expanding from $458 billion in 2025 to $755 billion by 2032. North America remains the sector's global leader, representing nearly half of worldwide revenues.

This growth is led by top-tier firms including Amgen Inc., AbbVie Inc., Pfizer Inc., and GlaxoSmithKline PLC (GSK), each advancing with new drug launches, R&D expansion, and strategic deals.

Amgen: Advancing Beyond Biosimilars

Amgen's $27.8B acquisition of Horizon Therapeutics (2023) bolstered its immunology portfolio. In April 2025, the FDA approved Uplizna for IgG4-related disease, marking a major post-merger win. Uplizna is now the first and only treatment available for this rare autoimmune condition.

The company is progressing olpasiran for cardiovascular risk and a GLP-1/GIP dual agonist for obesity, both headed for late-stage trials in 2026. Amgen is also expanding U.S. biologics production.

AbbVie: Post-Humira Growth Strategy

AbbVie is transitioning beyond Humira, whose U.S. sales dropped in 2024. Skyrizi and Rinvoq together generated over $17B and are projected to reach $31B by 2027.

A March 2025 partnership with Gubra positions AbbVie in the booming obesity drug market. FDA approvals for Rinvoq and Skyrizi in IBD further boost its portfolio. Oncology asset Epkinly, a bispecific antibody therapy co-developed with Genmab, also shows promise.

Pfizer: Oncology Expansion via Seagen

Pfizer is actively reshaping its growth strategy to reengineer its future growth following the decline of COVID-19-related revenue. The highlight is its $43 billion acquisition of Seagen, completed in December 2023. With this deal, Pfizer doubled its oncology pipeline and added four commercialized cancer drugs, including ADCETRIS and PADCEV. By May 2025, Phase 3 trials using ADCs were underway.

Recent approvals include Velsipity (ulcerative colitis) and Abrysvo (RSV vaccine). Pfizer is currently advancing its mRNA pipeline beyond infectious disease, targeting shingles and flu vaccines in collaboration with BioNTech.

GSK: Vaccine & Specialty Drug Momentum

GSK's Arexvy RSV vaccine earned $1.5B in 2023. In 2025, GSK followed up with FDA approval for Penmenvy, a new meningococcal vaccine, and Blujepa, a novel antibiotic for resistant UTIs.

The company also expects 14 major product launches through 2031, with each forecasted to exceed £2 billion in peak annual sales. To support these launches, GSK completed the acquisition of oncology-focused IDRx and continues to scale its U.S. R&D presence.

For retail investors, platforms like SoFi Invest (https://radcred.com/6ilv) offer accessible ways to gain exposure to healthcare and biotech sectors, aligning with long-term market trends.

Why Consider Investing in Biopharmaceutical Stocks Now?

1. Market projected to grow 7.4% annually through 2032

2. AbbVie and Pfizer offer strong dividends and innovation

3. Expanding pipelines and FDA-backed approvals

4. Long-term demand driven by aging demographics

5. M&A activity boosting company scale and value

6. Regulatory backing for accelerated drug development

Key Trends Driving Sector Growth

Several cross-sector trends are contributing to the biopharmaceutical market's strong outlook:

1. Aging Demographics: Rising need for chronic and specialty treatments

2. Tech-Driven Innovation: From mRNA to antibody-drug conjugates

3. Regulatory Acceleration: Over 60% of 2024 drug approvals were biologics

4. M&A Deals: Strategic acquisitions fueling growth pipelines

This M&A environment benefits both large pharma and emerging biotech investors.

Investor Outlook: Opportunity & Stability

As the market surges, investors are closely watching developments across leading biopharmaceutical companies. The industry offers a compelling blend of defensive stability and innovation-driven upside.

Firms like Amgen, AbbVie, GSK, and Pfizer are not only launching new products but also diversifying revenue streams and investing heavily in future pipeline assets.

SoFi Invest (https://radcred.com/6ilv) provides a streamlined way to tap into this growing market for investors looking to participate.

Conclusion: A Pivotal Decade for Biopharma

With FDA approvals accelerating, scientific innovation on the rise, and strategic investments reshaping pipelines, the U.S. biopharmaceutical sector is well-positioned for a strong decade. For those evaluating exposure to healthcare innovation, now is the time to explore options in the biopharma sector.

Authored by:
Marion Baxtar is a senior writer with the Kade Ventures Editorial Team. With over a decade of experience in financial journalism, she covers industry trends, regulatory shifts, and investment opportunities.

PR Team, Kade Ventures
Email: press@kadeventures.com
Phone: (555) 123-4567
Website: www.kadeventures.com
Address: 600 W.Broadway Suite 315 Glendale,CA 91204

Kade Ventures delivers market intelligence and investment insights across healthcare, biotech, and emerging tech. Our team of financial analysts and science journalists offers informed perspectives grounded in independent research and sector expertise.
We adhere to strict editorial standards and focus on transparent, actionable content for investors and industry professionals.

This release was published on openPR.